Trial Profile
A Phase I Open Label, Multi-Centre Study of AZD2281 Administered Orally in Combination With Cisplatin, to Assess the Safety and Tolerability in Patients With Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Dec 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Cisplatin
- Indications Advanced breast cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca; AstraZeneca AB
- 20 Dec 2023 Status changed from active, no longer recruiting to completed.
- 21 Oct 2023 This trail has been completed in Spain according to European Clinical Trials Database record.
- 19 Dec 2022 Planned End Date changed from 30 Dec 2022 to 30 Jun 2023.